The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a public listing that could see proceeds of around $210m. The cancer treatment-focused biotech ...
Jersey Mike’s reveals how modern IPOs transfer risk to investors while insiders exit. Why IPOs are liquidity events, not ...
As the global business community converges at Davos, we are seeing powerful catalysts driving M&A and capital markets activity. The foundational drivers that accelerated business activity in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results